SK Bioscience start to deliver Novavax COVID-19 vaccine

South Korea's SK Bioscience Co. announced on Tuesday that it started to deliver the Novavax COVID-19 vaccine against XBB.1.5 variant.According to No...

Moderna signs mRNA access deals with S.Korea's universities

The US biotech and pharmaceutical company Moderna on Friday announced signings of contracts with the academic-industry cooperation foundations of Ko...

SK Pharmteco secures 12 global pharma clients, sets up US R&D center

SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has secured 12 global pharm...

Lemonex signs MOU with WHO mRNA vaccines tech hub

South Korea's gene therapeutics developer Lemonex announced on Tuesday that it has signed a memorandum of understanding (MOU) with the World Health ...

GC Biopharma to develop mRNA flu vaccine with Canadian pharma

South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The dr...

Daewoong, Onchorus to undertake research on mRNA anticancer drugs

Daewoong Pharmaceutical said on Thursday that it has signed a joint R&D and commercialization agreement with America's biopharmaceutical venture...

Moderna to stay ahead in mRNA technology: CSO Melissa Moore

CAMBRIDGE, MA – The COVID-19 coronavirus disease has been a curse for many people and companies around the world over the past couple of years...

SK Bioscience seeks multi-billion-dollar M&As, eyes gene therapy sector

SK Bioscience Co., the biopharmaceutical unit of South Korea’s SK Group, is seeking multi-billion-dollar mergers and acquisitions to expand it...

Celltrion looks beyond biosimilars to develop its own mRNA drugs

South Korea’s Celltrion Inc. has long been a biosimilar player, producing replicas of original drugs, a growing market in the pandemic era.Ear...

Samsung Biologics-made Moderna vaccine available to Koreans this week

Moderna Inc.’s COVID-19 vaccine first produced by Samsung Biologics Co. under a contract manufacturing organization (CMO) service will be avai...

Samsung Biologics gears up to produce mRNA drug substance

South Korea’s Samsung Biologics Co. is gearing up for the drug substance (DS) sector of the messenger ribonucleic acid (mRNA)-based COVID-19 v...

Korean govt to spend $1.9 billion to become world’s leading vaccine maker

The South Korean government will invest 2.2 trillion won ($1.9 billion) by 2025 to become a top five vaccine producer in the world. President Moon J...

War for bio talent intensifies as S.Korea works on mRNA vaccines

As concerns rise over a resurgence of the COVID-19 pandemic, the war for talent in South Korea’s pharmaceutical industry is intensifying as th...

COVID treatment deals drive Samsung Bio’s record quarterly earnings

South Korea’s Samsung Biologics Co. posted its highest quarterly revenue and operating profit, thanks largely to a number of long-term manufac...

Eyegene to kick off Korea’s first mRNA clinical trial

Eyegene Inc. will be South Korea’s first vaccine maker to conduct clinical tests of messenger ribonucleic acid (mRNA) COVID-19 vaccines. Ealie...

Korea’s pharma consortium to develop mRNA vaccines by 2022

South Korea will develop its own messenger ribonucleic acid (mRNA) vaccines by next year with plans to annually manufacture 100 million doses from 2...

Samsung Bio plans to manufacture mRNA drug substance from 2022

Samsung Biologics will be entering the drug substance segment of the COVID-19 vaccine contract manufacturing business. According to industry sources...

Samsung Biologics to make Moderna’s mRNA vaccine from Q3

Samsung Biologics Co. will be manufacturing the US company Moderna’s COVID-19 vaccine (mRNA-1273) from the second half of this year in Korea. ...